This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Clemons, K. V.
Right arrow Articles by Stevens, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Clemons, K. V.
Right arrow Articles by Stevens, D. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 1998, p. 899-902, Vol. 42, No. 4
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Comparison of Fungizone, Amphotec, AmBisome, and Abelcet for Treatment of Systemic Murine Cryptococcosis

Karl V. Clemons* and David A. Stevens

California Institute for Medical Research and Division of Infectious Diseases, Department of Medicine, Santa Clara Valley Medical Center, San Jose, California 95128, and Division of Infectious Disease and Geographic Medicine, Department of Medicine, Stanford University, Stanford, California 94305

Received 6 October 1997/Returned for modification 8 December 1997/Accepted 2 February 1998

Three lipid-based formulations of amphotericin B have been approved for use in various countries. The aim of this study was to compare Amphotec (ABCD; Sequus), AmBisome (AmBi; Nexstar), Abelcet (ABLC; The Liposome Co.), and conventional deoxycholate amphotericin B (Fungizone; Bristol Meyers Squibb) for the treatment of experimental systemic cryptococcosis. A model was established in 10-week-old female CD-1 mice by intravenous (i.v.) injection of 6.25 × 105 viable Cryptococcus neoformans yeast cells. Therapy began 4 days later, with i.v. administration three times per week for 2 weeks. Mice received either no treatment, 1 mg of Fungizone per kg of body weight, or 1, 5, or 10 mg of ABCD, AmBi, or ABLC per kg. Ninety percent of control mice died between days 15 and 34. All treatment regimens except ABLC at 1 mg/kg prolonged survival compared with no treatment (P < 0.01 to 0.001). All mice receiving 5 or 10 mg of ABCD or AmBi per kg and 90% of mice given 10 mg of ABLC per kg survived, whereas <= 50% of those given other treatment regimens survived. Fungizone was the least effective of the four formulations, with 5 or 10 mg of ABCD, AmBi, or ABLC per kg resulting in a significantly better outcome than Fungizone (P < 0.001). Among the three formulations, ABCD and AmBi were equally effective, both being better than ABLC at equal 5- or 10-mg/kg doses (P < 0.001). Comparison of residual infectious burdens in various organs showed that each drug had some dose-responsive efficacy in three or more organs at escalating doses. In the brain, ABCD or AmBi at 5 or 10 mg/kg or ABLC at 10 mg/kg was more effective than Fungizone at 1 mg/kg or no treatment, while ABCD or AmBi at 1 mg/kg was as effective as ABLC at 10 mg/kg. Similar results were obtained for the kidneys and lungs. In the spleen, ABCD at 10 mg/kg cured all mice of infection and was superior to all other regimens. In the liver, AmBi at 5 mg/kg was superior to an equal dose of ABCD or ABLC. Overall, the efficacies of ABCD and AmBi were equal to that of Fungizone at 1 mg/kg and were about 10-fold better than that of ABLC, particularly in the brain; a comparative rank order of efficacies was ABCD congruent  AmBi > ABLC >> Fungizone. This is the first study that compared all four amphotericin B formulations.

* Corresponding author. Mailing address: Division of Infectious Diseases, Santa Clara Valley Medical Center, 751 S. Bascom Ave., San Jose, CA 95128-2699. Phone: (408) 998-4557. Fax: (408) 998-2723. E-mail: id.cimr{at}juno.com.

Antimicrobial Agents and Chemotherapy, April 1998, p. 899-902, Vol. 42, No. 4
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Olson, J. A., Adler-Moore, J. P., Jensen, G. M., Schwartz, J., Dignani, M. C., Proffitt, R. T. (2008). Comparison of the Physicochemical, Antifungal, and Toxic Properties of Two Liposomal Amphotericin B Products. Antimicrob. Agents Chemother. 52: 259-268 [Abstract] [Full Text]  
  • Hong, Y., Shaw, P. J., Nath, C. E., Yadav, S. P., Stephen, K. R., Earl, J. W., McLachlan, A. J. (2006). Population Pharmacokinetics of Liposomal Amphotericin B in Pediatric Patients with Malignant Diseases. Antimicrob. Agents Chemother. 50: 935-942 [Abstract] [Full Text]  
  • Andes, D., Safdar, N., Marchillo, K., Conklin, R. (2006). Pharmacokinetic-Pharmacodynamic Comparison of Amphotericin B (AMB) and Two Lipid-Associated AMB Preparations, Liposomal AMB and AMB Lipid Complex, in Murine Candidiasis Models. Antimicrob. Agents Chemother. 50: 674-684 [Abstract] [Full Text]  
  • Gonzalez, G. M., Tijerina, R., Najvar, L. K., Bocanegra, R., Rinaldi, M. G., Graybill, J. R. (2004). Efficacies of Amphotericin B (AMB) Lipid Complex, AMB Colloidal Dispersion, Liposomal AMB, and Conventional AMB in Treatment of Murine Coccidioidomycosis. Antimicrob. Agents Chemother. 48: 2140-2143 [Abstract] [Full Text]  
  • Clemons, K. V., Stevens, D. A. (2004). Comparative Efficacies of Four Amphotericin B Formulations--Fungizone, Amphotec (Amphocil), AmBisome, and Abelcet--against Systemic Murine Aspergillosis. Antimicrob. Agents Chemother. 48: 1047-1050 [Abstract] [Full Text]  
  • Takemoto, K., Yamamoto, Y., Ueda, Y., Sumita, Y., Yoshida, K., Niki, Y. (2004). Comparative studies on the efficacy of AmBisome and Fungizone in a mouse model of disseminated aspergillosis. J Antimicrob Chemother 53: 311-317 [Abstract] [Full Text]  
  • Clemons, K. V., Sobel, R. A., Williams, P. L., Pappagianis, D., Stevens, D. A. (2002). Efficacy of Intravenous Liposomal Amphotericin B (AmBisome) against Coccidioidal Meningitis in Rabbits. Antimicrob. Agents Chemother. 46: 2420-2426 [Abstract] [Full Text]  
  • Clemons, K. V., Lutz, J. E., Stevens, D. A. (2001). Efficacy of Recombinant Gamma Interferon for Treatment of Systemic Cryptococcosis in SCID Mice. Antimicrob. Agents Chemother. 45: 686-689 [Abstract] [Full Text]  
  • Lutz, J. E., Clemons, K. V., Stevens, D. A. (2000). Enhancement of antifungal chemotherapy by interferon-gamma in experimental systemic cryptococcosis. J Antimicrob Chemother 46: 437-442 [Abstract] [Full Text]  
  • Machard, S., Theodoro, F., Benech, H., Grognet, J.-M., Ezan, E. (2000). A Sensitive Amphotericin B Immunoassay for Pharmacokinetic and Distribution Studies. Antimicrob. Agents Chemother. 44: 546-550 [Abstract] [Full Text]  
  • Mullen, A. B., Baillie, A. J., Carter, K. C. (1998). Visceral Leishmaniasis in the BALB/c Mouse: A Comparison of the Efficacy of a Nonionic Surfactant Formulation of Sodium Stibogluconate with Those of Three Proprietary Formulations of Amphotericin B. Antimicrob. Agents Chemother. 42: 2722-2725 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»